JP2024528665A5 - - Google Patents

Info

Publication number
JP2024528665A5
JP2024528665A5 JP2024503420A JP2024503420A JP2024528665A5 JP 2024528665 A5 JP2024528665 A5 JP 2024528665A5 JP 2024503420 A JP2024503420 A JP 2024503420A JP 2024503420 A JP2024503420 A JP 2024503420A JP 2024528665 A5 JP2024528665 A5 JP 2024528665A5
Authority
JP
Japan
Prior art keywords
receptor agonist
amino acid
agonist according
monomer
full
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528665A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073832 external-priority patent/WO2023004282A2/en
Publication of JP2024528665A publication Critical patent/JP2024528665A/ja
Publication of JP2024528665A5 publication Critical patent/JP2024528665A5/ja
Pending legal-status Critical Current

Links

JP2024503420A 2021-07-19 2022-07-18 Il12受容体アゴニスト及びその使用方法 Pending JP2024528665A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163223534P 2021-07-19 2021-07-19
US63/223,534 2021-07-19
US202163233084P 2021-08-13 2021-08-13
US63/233,084 2021-08-13
US202163281580P 2021-11-19 2021-11-19
US63/281,580 2021-11-19
US202263337038P 2022-04-29 2022-04-29
US63/337,038 2022-04-29
PCT/US2022/073832 WO2023004282A2 (en) 2021-07-19 2022-07-18 Il12 receptor agonists and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024528665A JP2024528665A (ja) 2024-07-30
JP2024528665A5 true JP2024528665A5 (enExample) 2025-07-28

Family

ID=82846584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503420A Pending JP2024528665A (ja) 2021-07-19 2022-07-18 Il12受容体アゴニスト及びその使用方法

Country Status (10)

Country Link
US (2) US12522638B2 (enExample)
EP (1) EP4373851A2 (enExample)
JP (1) JP2024528665A (enExample)
KR (1) KR20240035845A (enExample)
AU (1) AU2022314734A1 (enExample)
CA (1) CA3226924A1 (enExample)
IL (1) IL310221A (enExample)
MX (1) MX2024000882A (enExample)
TW (1) TW202321282A (enExample)
WO (1) WO2023004282A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
AU2023294103A1 (en) * 2022-06-17 2024-12-19 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
KR20260030127A (ko) * 2023-06-27 2026-03-05 라이엘 이뮤노파마, 인크. Il-12 안정성 변이체
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
TW202523680A (zh) * 2023-12-07 2025-06-16 大陸商上海藥明生物技術有限公司 針對il-12受體的異二聚體蛋白
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2025160083A1 (en) * 2024-01-22 2025-07-31 Onko-Innate Pty Ltd Targeted low potency il-12 fc fusion proteins and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB9824437D0 (en) 1998-11-06 1999-01-06 Ylo Herttuala Seppo Gene therapy
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
WO2005049094A1 (en) 2003-11-13 2005-06-02 Advantagene, Inc. A mixed complementary viral vector for gene therapy
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
MY157915A (en) 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
TW201242976A (en) 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
US20170216387A1 (en) 2014-08-01 2017-08-03 Illycaffe' S.P.A. Roasted laurina coffee, method for its preparation, and use for preventing metabolic syndrome
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
ES2924402T3 (es) 2015-10-02 2022-10-06 Symphogen As Anticuerpos anti-PD-1 y composiciones
WO2017062953A1 (en) * 2015-10-10 2017-04-13 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
ES3034233T3 (en) 2016-01-22 2025-08-14 MabQuest SA Non-blocking pd1 specific antibodies
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
US12304935B2 (en) 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
US10696722B2 (en) 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
PH12019500668B1 (en) 2016-10-13 2023-12-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
WO2018144784A1 (en) 2017-02-01 2018-08-09 Smet Pharmaceutical Inc. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
EA202090149A1 (ru) 2017-06-28 2020-05-31 Ридженерон Фармасьютикалз, Инк. Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
JP7511542B2 (ja) 2018-08-30 2024-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質複合体を特徴づけるための方法
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
EP3766512A1 (en) 2019-07-16 2021-01-20 Universität Zürich Fc-modified il-12 for local cns delivery
BR112022001320A2 (pt) 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP7773991B2 (ja) 2020-03-23 2025-11-20 ザイムワークス ビーシー インコーポレイテッド マスクされたil12融合タンパク質及びその使用方法
JP7771076B2 (ja) 2020-04-01 2025-11-17 エクシリオ デベロップメント, インコーポレイテッド マスクされたil-12サイトカイン及びその切断産物
CN115916261A (zh) * 2020-04-17 2023-04-04 小利兰·斯坦福大学董事会 工程化il-12和il-23多肽及其用途
WO2022155263A2 (en) 2021-01-12 2022-07-21 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
US20240228586A1 (en) 2021-05-07 2024-07-11 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents

Similar Documents

Publication Publication Date Title
JP2024528665A5 (enExample)
JP7489468B2 (ja) 二重特異性融合タンパク質及びその応用
JP2022084852A (ja) キメラポリペプチド及びその使用
CN107847587B (zh) Cd30×cd16抗体与pd-1拮抗剂的联合药物
JP2020520665A5 (enExample)
Hornig et al. Evaluating combinations of costimulatory antibody–ligand fusion proteins for targeted cancer immunotherapy
JP7600328B2 (ja) PD-1とTGF-betaを標的とした四価二重特異性抗体、その製造方法および用途
US20080166336A1 (en) CD137 agonists to treat patients with IgE-mediated conditions
CN105330750A (zh) 一种快速中止car-t细胞杀伤作用的分子刹车及其用途
CN108463245A (zh) 具有修饰的j链的结合分子
CN108463472A (zh) 具有修饰的j-链的结合分子
EP2646465B1 (en) Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
WO2023045977A1 (zh) 白介素2突变体以及其融合蛋白
JP2024544559A5 (enExample)
JP2022553292A5 (enExample)
EP2441776A1 (en) Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
WO2023104214A1 (zh) 包含lrrc15抗原结合结构域的多特异性t细胞接合剂
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
JP2024544531A5 (enExample)
CN114075287B (zh) 人源化bcma抗体和bcma-car-t细胞
WO2024037628A1 (zh) 一种双特异性抗体及其应用
JP2023525555A5 (enExample)
JP2023516595A5 (enExample)
TWI914333B (zh) 一種雙特異性融合蛋白及其應用
Melero et al. Co-stimulation agonists via CD137, OX40, GITR, and CD27 for immunotherapy of cancer